WO2014051113A1 - Vegfc産生促進剤 - Google Patents
Vegfc産生促進剤 Download PDFInfo
- Publication number
- WO2014051113A1 WO2014051113A1 PCT/JP2013/076416 JP2013076416W WO2014051113A1 WO 2014051113 A1 WO2014051113 A1 WO 2014051113A1 JP 2013076416 W JP2013076416 W JP 2013076416W WO 2014051113 A1 WO2014051113 A1 WO 2014051113A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegfc
- rose oxide
- production promoter
- citronellyl acetate
- appropriate amount
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Definitions
- the present invention relates to an agent for improving swelling, lymphedema, wrinkle or obesity by inducing vascular endothelial growth factor C (VEGFC) expression and promoting activation of lymphatic vessel function.
- VEGFC vascular endothelial growth factor C
- the skin vascular system exists in the dermis and is composed of blood vessels and lymphatic vessels.
- tissue fluid that has moved out of the blood vessel must return to the vein again.
- Skin veins send blood efficiently to the center.
- the ability of the vein itself to take up tissue fluid is poor. From this, it has been understood that a tissue that takes in tissue fluid, that is, a lymphatic vessel, is an essential structure in the skin.
- Lymphatic vessels play an important role in maintaining a constant state of the microenvironment around the cells by collecting unwanted substances present in the skin, water that constantly leaks from blood vessels, and proteins. In addition, it has been considered to play a role of resisting infectious agents and external factors from the outside through the transport of T lymphocytes.
- Non-Patent Document 1 Jussila, L. & Alitalo, K. (2002) Physiol Rev 82, 673-700.
- function of lymphatic vessels is not limited to swelling, but also plays an important role in photoaging (wrinkle formation) of the skin associated with ultraviolet rays
- Non-patent Document 2 Kajiya, K. & Detmar, M. (2006) J Invest Dermatol 126, 919-21).
- VEGFR-3 was identified as a transmembrane receptor specifically present in lymphatic vessels, and VEGFC and VEGFD were found as ligands thereof.
- VEGFC acts on lymphatic vessels to promote lymphatic endothelial cell proliferation, migration, and lumen formation to activate lymphatic function (Non-patent document 1: Jussila, L. & Alitalo, K. (2002) Physiol Rev 82, 673-700).
- Non-patent Document 3 Saaristo, A., Tammela, T., Timonen, J., Yla-Herttuala, S., Tukiainen, E., Asko-Seljavaara, S. & Alitalo, K. (2004) Faseb J 18, 1707-9).
- Non-Patent Document 4 Harvey, NL, etc.
- Nat Genet 2005, 37, 1072-81 the VEGFC promoter is also expected as a therapeutic agent for obesity prevention that functionally forms lymphatic vessels.
- VEGF-A to E exist as VEGF family genes.
- VEGFB and VEGFE have been identified as factors that act only on blood vessels.
- VEGFA is known to be a factor that exists in the skin and works on lymphatic vessels but conversely deteriorates the function of lymphatic vessels (Non-patent Document 5: Nagy, J. A., Why, E., Feng) , D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., Dvorak, A M. & Dvorak, H. F. (2002) J Exp Med 196, 1497-506).
- VEGFD has been reported to be present in trace amounts in the dermis, but VEGFD is not an essential factor for skin lymphangiogenesis because VEGFD knockout mice do not cause any abnormalities in the formation and function of skin lymphatics.
- Non-Patent Document 6 Baldwin, M. E., Halford, M. M., Roufail, S., Williams, R. A., Hibbs, M. L., Grail, D., Kubo , H., Stacker, S. A. & Achen, M. G. (2005) Mol Cell Biol 25, 2441-9).
- VEGFC in the skin is strongly expressed in the epidermis.
- Non-patent Document 7 Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso , M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K. & Alitalo, K.
- Non-Patent Document 8 Makinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M. I., Pulkkanen, K. J., Kauppinen, R., D. G., Kubo, H., Nishikawa, S., Yla-Herttuala, S. & Alitalo, K.
- An object of the present invention is to find a novel component effective in preventing or controlling swelling, lymphedema, wrinkle formation, or obesity by inducing the expression of VEGFC and activating lymphatic vessel function.
- perfume ingredients such as rose oxide, citronellyl acetate and near uri oil induce the expression of VEGFC. That is, these components that induce the expression of VEGFC promote the activation of lymphatic function, and are extremely useful in preventing or suppressing swelling, lymphedema, wrinkle formation due to photoaging of the skin with ultraviolet rays, or obesity. I found it effective.
- a VEGFC production promoter comprising one or more kinds of components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- a lymphangiogenesis and / or function promoter comprising one or more components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- a swelling improving agent comprising one or more components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- An agent for improving lymphedema comprising one or more components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- a wrinkle improving agent comprising one or more components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- An obesity-improving agent comprising one or more components selected from the group consisting of rose oxide, citronellyl acetate and near uri oil.
- the VEGFC production promoter according to [1] which prevents or suppresses lymphedema.
- the lymphangiogenesis and / or function promoter according to [2] which prevents or suppresses lymphedema.
- a cosmetic or therapeutic method for preventing or suppressing swelling, lymphedema, wrinkle formation and / or obesity comprising the lymphangiogenesis and / or function promoter according to [2]. Applying to the skin of a subject in need of prevention or suppression of symptoms.
- vascular endothelial growth factor C (VEGFC) in vivo is induced by applying one or more components selected from the group consisting of rose oxide, citronellyl acetate and near urioil to the living body, and lymphatic vessel function Activation of is promoted. Such an action makes it possible to prevent or improve swelling, lymphedema, wrinkles, or obesity.
- the term “swelling” is used synonymously with “edema” and refers to a condition in which tissue fluid or lymph fluid accumulates in a cell, a cell gap, or a body cavity for some reason, and is found in subcutaneous tissue.
- the term “lymphedema” in the present specification refers to a state in which tissue fluid is accumulated in a peripheral portion due to obstruction of lymphatic vessels.
- screening for drugs that induce VEGFC is carried out by allowing various candidate fragrances to act on a HaCat cell line, which is a cultured cell derived from human epidermis, to quantify VEGFC.
- the amount of VEGFC was used as VEGFC-inducing activity, and a fragrance having VEGFC-inducing activity was selected as an active ingredient.
- Rose oxide Rose oxide And an organic compound having two asymmetric carbon atoms in the molecule. It has a sweet rose-like scent and is used in cosmetics and soaps as a pyran and monoterpene fragrance. Naturally, it can be obtained from rose, rose oil, apricot and peppermint, and there are multiple geometric and optical isomers.
- Industrially, allyl hydroperoxide obtained by the photooxidation reaction of citronellol is reduced with sodium sulfite to form a diol, and then cyclized with sulfuric acid to obtain the same amount of cis and trans forms.
- Commercial products as fragrances are mainly cis-racemic.
- Citronellyl acetate is an organic compound that exists as a colorless and transparent liquid at room temperature. Because it has a unique aroma similar to roses and lavender, it is used as a fragrance for food and cosmetics. It is naturally contained in essential oils such as citronella oil and geranium oil, and industrially synthesized from citronellol.
- Niaouli oil is an essential oil collected by steam distillation from the leaves or branches of Neuri (Melaleuca virdiflora), which is native to the Pacific region such as Indonesia, Australia and New Zealand and Madagascar Island in the Indian Ocean. It has bactericidal action and is used in cosmetics, soaps, bathing agents and the like.
- the fragrance component according to the present invention is extremely effective for promoting the formation and function of lymphatic vessels. Symptoms associated with lymphatic vessel dysfunction include not only swelling and lymphedema, but also photoaging of the skin (such as wrinkles) associated with ultraviolet rays, and obesity.
- the drug according to the present invention is effective for the prevention and suppression of skin photoaging due to ultraviolet rays and obesity as well as swelling and lymphedema. Furthermore, it is thought that the said fragrance
- UV Ultraviolet rays
- UVB intermediate UV
- the amount of UVB exposure necessary to cause photoaging is currently unknown.
- repeated exposure to UVB at levels that cause erythema and sunburn usually leads to photoaging.
- photoaging is rough skin, wrinkle formation, spot coloration, soil coloration, sagging formation, onset of telangiectasia, development of mole, onset of purpura, vulnerable, atrophy, fibrosis It can be specified as the occurrence of a pigment removal region, the development of a pre-malignant tumor, a malignant tumor, and the like. Photoaging usually occurs in skin that is habitually exposed to sunlight, such as the face, ears, head, neck and hands.
- the VEGFC production promoting agent, lymphangiogenesis and / or function promoting agent, swelling improving agent, lymphedema improving agent, wrinkle improving agent or obesity improving agent (hereinafter also referred to as “this agent”) of the present invention is used in accordance with its intended purpose.
- this agent the dosage, dosage form, and dosage form can be appropriately determined.
- the perfume ingredient in this drug is typically 0.0001 to 0.1%, preferably 0.001 to 0.01%, and optimally 0.005 to 0.01% of the total amount of the drug.
- the dosage form of this agent is not particularly limited and may be oral, parenteral, external, inhalation, etc. However, an external preparation for skin is preferred because it can work from both inhalation and transdermal.
- Examples of the dosage form include perfume, colon, shampoo and rinse, skin care, body shampoo, body rinse, body powder, fragrance, deodorant, bath preparation, lotion, cream, soap, dentifrice, aerosol products, etc. Any form generally used for cosmetics and other perfumes may be used. Furthermore, it can be used for pharmaceuticals such as inhalants.
- this agent also contains components that are usually used in skin preparations such as cosmetics and pharmaceuticals, such as whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, surfactants, A viscous agent, alcohols, a powder component, a colorant, an aqueous component, water, various skin nutrients, and the like can be appropriately blended as necessary.
- cosmetics and pharmaceuticals such as whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, surfactants, A viscous agent, alcohols, a powder component, a colorant, an aqueous component, water, various skin nutrients, and the like can be appropriately blended as necessary.
- the human epidermis-derived cultured cells HaCaT cells (German Cancer Research Center, Heidelberg, Germany) are cultured in DMEM medium (Gibco low glucose DMEM, Life technologies TM) containing 10% FBS (Standard fetal bovine serum, Hyclone).
- DMEM medium Gibco low glucose DMEM, Life technologies TM
- FBS Standard fetal bovine serum, Hyclone
- the well plate was seeded so that the number of cells per well was 15 ⁇ 10 4 . 24 hours after sowing, the medium was replaced with serum-free DMEM and cultured for 24 hours. Thereafter, various flavors dissolved in ethanol were added (the final concentration of the flavor was 0.001 to 0.01%). Ethanol was used as a control.
- Emulsion formulation (wt%) (1) Stearic acid 2.0 (2) Cetyl alcohol 1.5 (3) Vaseline 4.0 (4) Squalane 5.0 (5) Glycerol tree 2-ethylhexanoate 2.0 (6) Sorbitan monooleate 2.0 (7) Dipropylene glycol 5.0 (8) PEG 1500 0.3 (9) Triethanolamine 0.1 (10) Preservative appropriate amount (11) VEGFC production promoter of the present invention: citronellyl acetate 0.01 (12) Purified water residue
- Emulsion formulation (wt%) (1) Ethyl alcohol 10.0 (2) Cyclomethicone 0.1 (3) Butylene glycol 5.0 (4) Dimethicone 3.0 (5) Glycene 0.1 (6) Menthol 1.0 (7) Trimethylsiloxysilicic acid 0.1 (8) Caffeine 1.0 (9) Trimethylglycine 1.0 (10) Xanthan gum 0.001 (11) Hydroxyethyl cellulose 0.1 (12) Fermented soybean extract 1.0 (13) Lauryl betaine 0.5 (14) Carbomer 0.2 (15) Chelating agent Appropriate amount (16) Paraben Appropriate amount (17) Benzoic acid Appropriate amount (18) VEGFC production promoter of the present invention: Rose oxide 0.01 (19) Iron oxide appropriate amount (20) Caustic potash 0.05 (21) Dicalcium glycyrrhizinate 0.01 (22) Pyridoxine hydrochloride 0.01 (23) Ascorbic acid glucoside 0.01 (24) Arbutin 3.0 (25) Yukinoshit
- Emulsion formulation (wt%) (1) Butylene glycol 4.0 (2) Propylene glycol 4.0 (3) Carbomer 0.2 (4) Caustic potash 0.2 (5) Behenic acid 0.5 (6) Stearic acid 0.5 (7) Isostearic acid 0.5 (8) Glyceryl stearate 1.0 (9) Glyceryl isostearate 1.0 (10) Behenyl alcohol 0.5 (11) Squalane 5.0 (12) Trioctanoin 3.0 (13) Phenyltrimethicone 2.0 (14) Batyl alcohol 0.5 (15) Dicalcium glycyrrhizinate 0.01 (16) Preservative Appropriate amount (17) Chelating agent Appropriate amount (18) Pigment Appropriate amount (19) VEGFC production promoter of the present invention: near urioil 0.15 (20) Purified water residue
- Cream formula (wt%) (1) Glycerin 10.0 (2) Butylene glycol 5.0 (3) Carbomer 0.1 (4) Caustic potash 0.2 (5) Stearic acid 2.0 (6) Glyceryl stalate 2.0 (7) Glyceryl isostearate 2.0 (8) Vaseline 5.0 (9) Preservative appropriate amount (10) Antioxidant appropriate amount (11) VEGFC production promoter of the present invention: citronellyl acetate 0.02 (12) Purified water Residual (13) Chelating agent Appropriate amount (14) Pigment Appropriate amount (15) Stearyl alcohol 2.0 (16) Behenyl alcohol 2.0 (17) Palm hardened oil 2.0 (18) Squalane 10.0 (19) Potassium 4-methoxysalicylate 3.0
- Formula (wt%) Cream (1) Glycerin 3.0 (2) Dipropylene glycol 7.0 (3) Polyethylene glycol 3.0 (4) Glyceryl stearate 3.0 (5) Glyceryl isostearate 2.0 (6) Stearyl alcohol 2.0 (7) Behenyl alcohol 2.0 (8) Liquid paraffin 7.0 (9) Cyclomethicone 3.0 (10) Dimethicone 1.0 (11) Octyl methoxycinnamate 0.1 (12) Na hyaluronate 0.05 (13) Preservative appropriate amount (14) Antioxidant appropriate amount (15) VEGFC production promoter of the present invention: Rose oxide 0.02 (16) Purified water Residual (17) Chelating agent appropriate amount (18) Pigment appropriate amount
- Aerosol formulation (wt%) (1) Glycerin 2.0 (2) Dipropylene glycol 2.0 (3) PEG-60 hydrogenated castor oil 0.3 (4) HPCCD 1.0 (5) Preservative appropriate amount (6) chelating agent appropriate amount (7) dye appropriate amount (8) VEGFC production promoter of the present invention: near uri oil 0.1 (9) Purified water appropriate amount (10) LPG remaining
- Aerosol formulation (wt%) (1) Ethanol 60.0 (2) Lactic acid menthyl 0.1 (3) Sodium lactate 0.1 (4) Tocopherol acetate 0.01 (5) Lactic acid 0.01 (6) Caffeine 0.01 (7) Fennel extract 1.0 (8) Hamelis Extract 1.0 (9) Dokudami Extract 1.0 (10) Dipropylene glycol 1.0 (11) Nitrogen gas 0.9 (12) Polyoxyethylene polyoxypropylene 1.0 Decyl tetradecyl ether (13) Butylene glycol 2.0 (14) Tocopherol 0.05 (15) VEGFC production promoter of the present invention 0.01 (16) PEG-60 hydrogenated castor oil 0.1 (17) Water residue
- Fragrance prescription (wt%) (1) Alcohol 75.0 (2) Purified water Residual (3) Dipropylene glycol 5.0 (4) VEGFC production promoter of the present invention: citronellyl acetate 1.0 (5) Antioxidant 8.0 (6) Appropriate amount of dye (7) Appropriate amount of UV absorber
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、VEGFC産生促進剤。
[2] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、リンパ管新生及び/又は機能促進剤。
[3] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、むくみ改善剤。
[4] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、リンパ浮腫改善剤。
[5] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、しわ改善剤。
[6] ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を含有することを特徴とする、肥満改善剤。
[7] むくみを防止又は抑制する、[1]に記載のVEGFC産生促進剤。
[8] むくみを防止又は抑制する、[2]に記載のリンパ管新生及び/又は機能促進剤。
[9] リンパ浮腫を防止又は抑制する、[1]に記載のVEGFC産生促進剤。
[10] リンパ浮腫を防止又は抑制する、[2]に記載のリンパ管新生及び/又は機能促進剤。
[11] しわの形成を防止又は抑制する、[1]に記載のVEGFC産生促進剤。
[12] しわの形成を防止又は抑制する、[2]に記載のリンパ管新生及び/又は機能促進剤。
[13] 肥満を防止又は抑制する、[1]に記載のVEGFC産生促進剤。
[14] 肥満を防止又は抑制する、[2]に記載のリンパ管新生及び/又は機能促進剤。
[15] むくみ、リンパ浮腫、しわの形成及び/又は肥満を防止又は抑制するための美容的又は治療的方法であって、[1]に記載のVEGFC産生促進剤を、これらの症状の防止又は抑制が必要な対象の皮膚に塗布することを含んで成る方法。
[16] むくみ、リンパ浮腫、しわの形成及び/又は肥満を防止又は抑制するための美容的又は治療的方法であって、[2]に記載のリンパ管新生及び/又は機能促進剤を、これらの症状の防止又は抑制が必要な対象の皮膚に塗布することを含んで成る方法。
[19] むくみ、リンパ浮腫、しわの形成及び/又は肥満を防止又は抑制するための、[1]に記載のVEGFC産生促進剤の使用。
[20] むくみ、リンパ浮腫、しわの形成及び/又は肥満を防止又は抑制するための、[2]に記載のリンパ管新生及び/又は機能促進剤の使用。
本明細書における用語、「むくみ」とは、「浮腫」と同義で用いられ、組織液又はリンパ液がなんらかの原因により細胞内、細胞間隙、又は体腔内に貯留する状態であって、皮下組織においてみられる。更に本明細書における用語、「リンパ浮腫」とは、リンパ管の閉塞により、末梢の部分に組織液が貯留する状態をいう。
ローズオキサイドは、
シトロネリルアセテートは、
ニアウリオイルは、インドネシア、オーストラリア、ニュージーランドなどの太平洋地域やインド洋のマダガスカル島を原産とするフトモモ科植物であるニアウリ(学名Melaleuca virdiflora)の葉又は枝から水蒸気蒸留により採取される精油である。殺菌作用を有し、化粧品、石鹸、入浴剤などに用いられている。
以下、本発明のVEGFC産生促進剤の配合例を示すが、本発明の実施は以下に限定されるものではない。
処方 (重量%)
(1)グリセリン 2.0
(2)ジプロピレングリコール 2.0
(3)PEG-60 水添ひまし油 0.3
(4)トリメチルグリシン 0.1
(5)防腐剤 適量
(6)キレート剤 適量
(7)染料 適量
(8)本発明のVEGFC産生促進剤:ローズオキサイド 0.05
(9)精製水 残余
処方 (重量%)
(1)アルコール 30.0
(2)ブチレングリコール 4.0
(3)グリセリン 2.0
(4)PPG-13デシルテトラデス24 0.3
(5)オクチルメトキシシンナメート 0.1
(6)メントール 0.2
(7)酢酸トコフェロール 0.1
(8)キレート剤 適量
(9)染料 適量
(10)本発明のVEGFC産生促進剤:ニアウリオイル 0.1
(11)精製水 残余
処方 (重量%)
(1)ステアリン酸 2.0
(2)セチルアルコール 1.5
(3)ワセリン 4.0
(4)スクワラン 5.0
(5)グリセロールトリー2-エチルヘキサン酸エステル 2.0
(6)ソルビタンモノオレイン酸エステル 2.0
(7)ジプロピレングリコール 5.0
(8)PEG1500 0.3
(9)トリエタノールアミン 0.1
(10)防腐剤 適量
(11)本発明のVEGFC産生促進剤:シトロネリルアセテート 0.01
(12)精製水 残余
処方 (重量%)
(1)エチルアルコール 10.0
(2)シクロメチコン 0.1
(3)ブチレングリコール 5.0
(4)ジメチコン 3.0
(5)グリセン 0.1
(6)メントール 1.0
(7)トリメチルシロキシケイ酸 0.1
(8)カフェイン 1.0
(9)トリメチルグリシン 1.0
(10)キサンタンガム 0.001
(11)ヒドロキシエチルセルロース 0.1
(12)大豆発酵エキス 1.0
(13)ラウリルベタイン 0.5
(14)カルボマー 0.2
(15)キレート剤 適量
(16)パラベン 適量
(17)安息香酸 適量
(18)本発明のVEGFC産生促進剤:ローズオキサイド 0.01
(19)酸化鉄 適量
(20)苛性カリ 0.05
(21)グリチルリチン酸ジカルシウム 0.01
(22)塩酸ピリドキシン 0.01
(23)アスコルビン酸グルコシド 0.01
(24)アルブチン 3.0
(25)ユキノシタ抽出液 0.1
(26)水 残余
処方 (重量%)
(1)ブチレングリコール 4.0
(2)プロピレングリコール 4.0
(3)カルボマー 0.2
(4)苛性カリ 0.2
(5)ベヘニン酸 0.5
(6)ステアリン酸 0.5
(7)イソステアリン酸 0.5
(8)ステアリン酸グリセリル 1.0
(9)イソステアリン酸グリセリル 1.0
(10)ベヘニルアルコール 0.5
(11)スクワラン 5.0
(12)トリオクタノイン 3.0
(13)フェニルトリメチコン 2.0
(14)バチルアルコール 0.5
(15)グリチルリチン酸ジカルシウム 0.01
(16)防腐剤 適量
(17)キレート剤 適量
(18)顔料 適量
(19)本発明のVEGFC産生促進剤:ニアウリオイル 0.15
(20)精製水 残余
処方 (重量%)
(1)グリセリン 10.0
(2)ブチレングリコール 5.0
(3)カルボマー 0.1
(4)苛性カリ 0.2
(5)ステアリン酸 2.0
(6)スタリン酸グリセリル 2.0
(7)イソステアリン酸グリセリル 2.0
(8)ワセリン 5.0
(9)防腐剤 適量
(10)酸化防止剤 適量
(11)本発明のVEGFC産生促進剤:シトロネリルアセテート 0.02
(12)精製水 残余
(13)キレート剤 適量
(14)顔料 適量
(15)ステアリルアルコール 2.0
(16)ベヘニルアルコール 2.0
(17)パーム硬化油 2.0
(18)スクワラン 10.0
(19)4-メトキシサリチル酸カリウム 3.0
クリーム
(1)グリセリン 3.0
(2)ジプロピレングリコール 7.0
(3)ポリエチレングリコール 3.0
(4)ステアリン酸グリセリル 3.0
(5)イソステアリン酸グリセリル 2.0
(6)ステアリルアルコール 2.0
(7)ベヘニルアルコール 2.0
(8)流動パラフィン 7.0
(9)シクロメチコン 3.0
(10)ジメチコン 1.0
(11)オクチルメトキシシンナメート 0.1
(12)ヒアルロン酸Na 0.05
(13)防腐剤 適量
(14)酸化防止剤 適量
(15)本発明のVEGFC産生促進剤:ローズオキサイド 0.02
(16)精製水 残余
(17)キレート剤 適量
(18)顔料 適量
処方 (重量%)
(1)エチルアルコール 10.0
(2)グリセリン 5.0
(3)ブチレングリコール 5.0
(4)カルボマー 0.5
(5)アミノメチルプロパノール 0.3
(6)PEG-60水添ヒマシ油 0.3
(7)メントール 0.02
(8)防腐剤 適量
(9)キレート剤 適量
(10)本発明のVEGFC産生促進剤:シトロネリルアセテート 0.01
(11)精製水 残余
処方 (重量%)
(1)グリセリン 2.0
(2)ジプロピレングリコール 2.0
(3)PEG-60水添ヒマシ油 0.3
(4)HPPCD 1.0
(5)防腐剤 適量
(6)キレート剤 適量
(7)染料 適量
(8)本発明のVEGFC産生促進剤:ニアウリオイル 0.1
(9)精製水 適量
(10)LPG 残余
処方 (重量%)
(1)エタノール 60.0
(2)乳酸メンチル 0.1
(3)乳酸ナトリウム 0.1
(4)酢酸トコフェロール 0.01
(5)乳酸 0.01
(6)カフェイン 0.01
(7)ウイキョウエキス 1.0
(8)ハマメリスエキス 1.0
(9)ドクダミエキス 1.0
(10)ジプロピレングリコール 1.0
(11)窒素ガス 0.9
(12)ポリオキシエチレンポリオキシプロピレン 1.0
デシルテトラデシルエーテル
(13)ブチレングリコール 2.0
(14)トコフェロール 0.05
(15)本発明のVEGFC産生促進剤 0.01
(16)PEG-60水添ヒマシ油 0.1
(17)水 残余
処方 (重量%)
(1)アルコール 75.0
(2)精製水 残余
(3)ジプロピレングリコール 5.0
(4)本発明のVEGFC産生促進剤:シトロネリルアセテート 1.0
(5)酸化防止剤 8.0
(6)色素 適量
(7)紫外線吸収剤 適量
処方 (重量%)
(1)硫酸ナトリウム 45.0
(2)炭酸水素ナトリウム 45.0
(3)ラベンダーオイル 9.0
(4)本発明のVEGFC産生促進剤: ニアウリオイル 1.0
処方 (重量%)
(1)エリスリトール 2.0
(2)カフェイン 5.0
(3)オウバク抽出物 3.0
(4)グリセリン 50.0
(5)カルボキシビニルポリマー 0.4
(6)ポリエチレングリコール400 30.0
(7)エデト3ナトリウム 0.1
(8)ポリオキシレン(10)メチルポリシロキサン共重合体 2.0
(9)スクワラン 1.0
(10)水酸化カリウム 0.15
(11)本発明のVEGFC産生促進剤:ローズオキサイド 0.01
処方 (重量%)
(1)固形パラフィン 5.0
(2)ミツロウ 10.0
(3)ワセリン 15.0
(4)流動パラフィン 41.0
(5)1.3-ブチレングリコール 4.0
(6)モノステアリン酸グリセリン 2.0
(7)POE(20)ソルビタンモノラウリン酸エステル 2.0
(8)ホウ砂 0.2
(9)カフェイン 2.0
(10)防腐剤 適量
(11)酸化防止剤 適量
(12)本発明のVEGFC産生促進剤:ニアウリオイル 1.0
(13)精製水 残余
Claims (6)
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、VEGFC産生促進剤。
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、リンパ管新生及び/又は機能促進剤。
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、むくみ改善剤。
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、リンパ浮腫改善剤。
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、しわ改善剤。
- ローズオキサイド、シトロネリルアセテート及びニアウリオイルから成る群から選定される1又は複数種の成分を活性成分として含有することを特徴とする、肥満改善剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014538657A JP6061940B2 (ja) | 2012-09-28 | 2013-09-27 | Vegfc産生促進剤 |
EP13841176.4A EP2902022B1 (en) | 2012-09-28 | 2013-09-27 | Vegfc production promoter |
KR1020157010860A KR102135989B1 (ko) | 2012-09-28 | 2013-09-27 | Vegfc 생산 촉진제 |
US14/431,837 US20150328137A1 (en) | 2012-09-28 | 2013-09-27 | Vegfc production promoter |
CN201380061795.0A CN104918614B (zh) | 2012-09-28 | 2013-09-27 | Vegfc产生促进剂 |
HK16102913.2A HK1214950A1 (zh) | 2012-09-28 | 2016-03-14 | 產生促進劑 |
US15/625,080 US10624829B2 (en) | 2012-09-28 | 2017-06-16 | VEGFC production promoter |
US16/827,033 US11213472B2 (en) | 2012-09-28 | 2020-03-23 | VEGFC production promoter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-218612 | 2012-09-28 | ||
JP2012218612 | 2012-09-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/431,837 A-371-Of-International US20150328137A1 (en) | 2012-09-28 | 2013-09-27 | Vegfc production promoter |
US15/625,080 Continuation US10624829B2 (en) | 2012-09-28 | 2017-06-16 | VEGFC production promoter |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014051113A1 true WO2014051113A1 (ja) | 2014-04-03 |
Family
ID=50388502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/076416 WO2014051113A1 (ja) | 2012-09-28 | 2013-09-27 | Vegfc産生促進剤 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150328137A1 (ja) |
EP (1) | EP2902022B1 (ja) |
JP (1) | JP6061940B2 (ja) |
KR (1) | KR102135989B1 (ja) |
CN (1) | CN104918614B (ja) |
HK (1) | HK1214950A1 (ja) |
TW (1) | TWI653055B (ja) |
WO (1) | WO2014051113A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3165216A1 (de) * | 2015-11-05 | 2017-05-10 | Basf Se | Texturierte zusammensetzung |
KR20230080056A (ko) | 2021-11-29 | 2023-06-07 | (주)아모레퍼시픽 | 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제 |
CN114469906A (zh) * | 2022-03-16 | 2022-05-13 | 中国农业大学 | 香茅醇在制备抗皮肤光损伤产品中的用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004002258A (ja) | 2002-04-01 | 2004-01-08 | Noevir Co Ltd | Vegf産生促進剤 |
JP2005298487A (ja) * | 2004-03-16 | 2005-10-27 | Shiseido Co Ltd | 女性ホルモン調節機能調整用香料組成物 |
JP2006056845A (ja) * | 2004-08-23 | 2006-03-02 | Teikoku Seiyaku Co Ltd | バラ科植物抽出物を含有する貼布剤 |
JP2006241044A (ja) * | 2005-03-02 | 2006-09-14 | Shiseido Co Ltd | エストロゲン様作用剤 |
WO2007026645A1 (ja) * | 2005-08-31 | 2007-03-08 | Nature Technology Inc. | 植物精油成分を有効成分とするダイエット用組成物、その組成物を含むダイエット用シート状組成物及び経皮吸収型ダイエット用医薬製剤、並びにこれらの製造方法 |
JP2008189609A (ja) | 2007-02-06 | 2008-08-21 | Shiseido Co Ltd | Vegfc産生促進剤 |
WO2009093534A1 (ja) * | 2008-01-21 | 2009-07-30 | Shiseido Company, Ltd. | Vegfc産生促進剤 |
JP2013155122A (ja) * | 2012-01-27 | 2013-08-15 | Shiseido Co Ltd | 幹細胞賦活化剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4206090A (en) * | 1978-10-06 | 1980-06-03 | International Flavors & Fragrances Inc. | 3-Methyl-1-phenyl-pentanol-5 or its isomer and butanoyl cyclohexane derivatives |
US5260313A (en) * | 1992-03-12 | 1993-11-09 | National Pain Institute, Inc. | Diagnosis and treatment of various neuralgias |
IT1297080B1 (it) * | 1997-11-26 | 1999-08-03 | Andrea Carnevali | Composizione per il trattamento di ustioni, eritemi solari, abrasioni, piaghe e irritazioni cutanee |
FR2781162B1 (fr) * | 1998-07-17 | 2000-11-17 | Andre Mazaury | Procede de traitement cosmetique de la peau, du cuir chevelu et de leurs derives utilisant des ondes electro-magnetiques et des huiles essentielles |
US20040235742A1 (en) * | 1999-08-10 | 2004-11-25 | Santen Pharmaceutical Co., Ltd. | Water channel opener compositions and medicinal compositions for ophthalmic use |
AU2002249519B2 (en) * | 2002-03-25 | 2009-11-12 | Council Of Scientific And Industrial Research | Essential oil with citronellol and rose oxides from dracocephalum heterophyllum benth and a process thereof |
JP2005006287A (ja) | 2003-05-20 | 2005-01-06 | Hitachi Ltd | パイロット信号の送受信方法及び基地局装置及び端末装置 |
DE10335634B4 (de) * | 2003-08-01 | 2007-06-06 | Dr. André Rieks, Labor für Enzymtechnologie GmbH | Verwendung von Perilla-, Geranium- und Citronellsäure sowie ausgewählten Derivaten zur Konservierung, zur Behandlung von Akne, Schuppen oder Dematomykosen sowie zur Bekämpfung Körpergeruch verursachender Mikroorganismen |
CA2676139C (en) * | 2007-02-06 | 2016-04-26 | Origin Biomed Inc. | Composition comprising terpene compounds and methods for inhibiting nerve transmission |
KR101199672B1 (ko) * | 2008-02-01 | 2012-11-09 | 마리 케이 인코포레이티드 | 방향성 피부활성 성분을 사용하여 피부를 치료하는 방법 |
CN101619263A (zh) * | 2008-07-02 | 2010-01-06 | 张衍华 | 一种决明子香精的配制方法 |
US20100196521A1 (en) * | 2009-02-05 | 2010-08-05 | Liu Yuk Kwan | Formulation for the treatment of hypoxia and related disorders |
WO2011034591A1 (en) * | 2009-09-17 | 2011-03-24 | New York University | Methods of blocking ultraviolet radiation and promoting skin growth using terpenes and terpenoids |
CN102151310A (zh) * | 2010-02-11 | 2011-08-17 | 张金荣 | 一种消炎散肿的外用制剂及制法和检测方法 |
-
2013
- 2013-09-27 JP JP2014538657A patent/JP6061940B2/ja active Active
- 2013-09-27 KR KR1020157010860A patent/KR102135989B1/ko active IP Right Grant
- 2013-09-27 US US14/431,837 patent/US20150328137A1/en not_active Abandoned
- 2013-09-27 EP EP13841176.4A patent/EP2902022B1/en active Active
- 2013-09-27 CN CN201380061795.0A patent/CN104918614B/zh active Active
- 2013-09-27 WO PCT/JP2013/076416 patent/WO2014051113A1/ja active Application Filing
- 2013-09-27 TW TW102135229A patent/TWI653055B/zh not_active IP Right Cessation
-
2016
- 2016-03-14 HK HK16102913.2A patent/HK1214950A1/zh not_active IP Right Cessation
-
2017
- 2017-06-16 US US15/625,080 patent/US10624829B2/en active Active
-
2020
- 2020-03-23 US US16/827,033 patent/US11213472B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004002258A (ja) | 2002-04-01 | 2004-01-08 | Noevir Co Ltd | Vegf産生促進剤 |
JP2005298487A (ja) * | 2004-03-16 | 2005-10-27 | Shiseido Co Ltd | 女性ホルモン調節機能調整用香料組成物 |
JP2006056845A (ja) * | 2004-08-23 | 2006-03-02 | Teikoku Seiyaku Co Ltd | バラ科植物抽出物を含有する貼布剤 |
JP2006241044A (ja) * | 2005-03-02 | 2006-09-14 | Shiseido Co Ltd | エストロゲン様作用剤 |
WO2007026645A1 (ja) * | 2005-08-31 | 2007-03-08 | Nature Technology Inc. | 植物精油成分を有効成分とするダイエット用組成物、その組成物を含むダイエット用シート状組成物及び経皮吸収型ダイエット用医薬製剤、並びにこれらの製造方法 |
JP2008189609A (ja) | 2007-02-06 | 2008-08-21 | Shiseido Co Ltd | Vegfc産生促進剤 |
WO2009093534A1 (ja) * | 2008-01-21 | 2009-07-30 | Shiseido Company, Ltd. | Vegfc産生促進剤 |
JP2013155122A (ja) * | 2012-01-27 | 2013-08-15 | Shiseido Co Ltd | 幹細胞賦活化剤 |
Non-Patent Citations (23)
Title |
---|
BALDWIN, M.E.; HALFORD, M.M.; ROUFAIL, S.; WILLIAMS, R.A.; HIBBS, M.L.; GRAIL, D.; KUBO, H.; STACKER, S.A.; ACHEN, M.G., MOL. CELL. BIOL., vol. 25, 2005, pages 2441 - 9 |
BOSKABADY MH ET AL.: "Pharmacological effects of Rosa damascena", IRAN J BASIC MED SCI, vol. 14, no. 4, 2011, pages 295 - 307, XP055240761 * |
FASEB. J., vol. 18, 2004, pages 1707 - 9 |
HARVEY, N.L. ET AL., NAT. GENET., vol. 37, 2005, pages 1072 - 81 |
J. EXP. MED., vol. 196, 2002, pages 1497 - 506 |
J. INVEST. DERMATOL., vol. 126, 2006, pages 919 - 21 |
JAPAN PERFUMERY ET AL., KAORI NO HYAKKA, 20 September 1997 (1997-09-20), pages 453 - 456, XP008178616 * |
JELTSCH, M.; KAIPEINEN, A.; JOUKOV, V.; MENG, X.; LAKSO, M.; RAUVALA, H.; SWARTZ, M.; FUKUMURA, D.; JAIN, R.K.; ALITALO, K., SCIENCE, vol. 276, 1997, pages 1423 - 5 |
JUSILLA, L.; ALITALO, K., PHYSIOL. REV., vol. 82, 2002, pages 673 - 700 |
KAJIYA, K.; DETMAR, M., J. INVEST. DERMATOL., vol. 126, 2006, pages 919 - 21 |
KENTARO KAJIYA ET AL.: "A Novel Mechanism of Cutaneous Photo-Aging Mediated by the Impairment of Lymphatic Function and the Protective Role of a Lymphatic-promoting Compound", FRAGRANCE JOURNAL 0288-9803, November 2009 (2009-11-01), pages 91, XP008178606 * |
MAKINEN, T.; JUSSILA, L; VEIKKOLA, T.; KARPANEN, T.; KETTUNEN, M.I.; PULKKANEN, K.J.; KAUPPINEN, R.; JACKSON, D.G.; KUBO, H.; NISH, NAT. MED., vol. 7, 2001, pages 199 - 205 |
MOL. CELL. BIOL., vol. 25, 2005, pages 2441 - 9 |
NAGY, J.A.; VASILE, E.; FENG, D.; SUNDBERG, C; BROWN, L.F.; DETMAR, M.J.; LAWITTS, J.A.; BENJAMIN, L.; TAN, X.; MANSEAU, E.J., J. EXP. MED., vol. 196, 2002, pages 1497 - 506 |
NAT. GENET., vol. 37, 2005, pages 1072 - 81 |
NAT. MED., vol. 7, 2001, pages 199 - 205 |
PHYSIOL. REV., vol. 82, 2002, pages 673 - 700 |
SAARISTO A ET AL.: "Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds", FASEB J, vol. 18, no. 14, 2004, pages 1707 - 1709, XP009045161 * |
SAARISTO, A.; TAMMELA, T.; TIMONEN, J.; YLA-HERTTUALA, S.; TUKIANEN, E.; ASKO-SELJAVAARA, S.; ALITALO, K., FASEB. J., vol. 18, 2004, pages 1707 - 9 |
SCIENCE, vol. 276, 1997, pages 1423 - 5 |
SHISEIDO: "Hana no Hoko Seibun ni Rinpa-kan no Kyoka Sayo o Hakken", NIKKEI BIOTECHNOLOGY, 28 October 2013 (2013-10-28), XP055241421, Retrieved from the Internet <URL:https://bio.nikkeibp.co.jp/article/news/20131027/171678> * |
SHISEIDO: "Rinpa-kan no Kino Teika ga Shiwa Keisei no Gen'in de aru Koto o Kaimei", FRAGRANCE JOURNAL, April 2008 (2008-04-01), pages 7, XP008178605 * |
SHISEIDO: "Tennen no Bara no Kaori Seibun no Hifu Seiri Koka o Hakken", NIKKAN KOGYO SHINBUN, 30 October 2013 (2013-10-30), XP008178613, Retrieved from the Internet <URL:http://www.nikkan.co.jp/news/nkx1020131030ceba.html> * |
Also Published As
Publication number | Publication date |
---|---|
EP2902022A4 (en) | 2016-03-23 |
KR20150063485A (ko) | 2015-06-09 |
TW201417835A (zh) | 2014-05-16 |
KR102135989B1 (ko) | 2020-07-20 |
JPWO2014051113A1 (ja) | 2016-08-25 |
US20150328137A1 (en) | 2015-11-19 |
CN104918614B (zh) | 2018-10-16 |
US20200222294A1 (en) | 2020-07-16 |
HK1214950A1 (zh) | 2016-08-12 |
EP2902022B1 (en) | 2020-10-28 |
TWI653055B (zh) | 2019-03-11 |
JP6061940B2 (ja) | 2017-01-18 |
US10624829B2 (en) | 2020-04-21 |
EP2902022A1 (en) | 2015-08-05 |
US20170281500A1 (en) | 2017-10-05 |
CN104918614A (zh) | 2015-09-16 |
US11213472B2 (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6446408B2 (ja) | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 | |
CN102448450B (zh) | 包含反式-叔丁基环己醇作为皮肤刺激缓解剂的组合物 | |
JP2021519774A (ja) | 皮膚の処置におけるレチノールの代替 | |
CN103025310A (zh) | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 | |
US20090036545A1 (en) | Skin appearance through gene manipulation | |
US11213472B2 (en) | VEGFC production promoter | |
CA3011834C (en) | Skin cosmetic composition comprising saccharin, maltol, and theobromine | |
CN107530273A (zh) | 含有缬草提取物的组合物 | |
JP5645344B2 (ja) | 外用剤組成物 | |
JP2014129267A (ja) | Dna損傷抑制剤 | |
JP2014122183A (ja) | Dna損傷抑制剤 | |
JP2009242311A (ja) | Scf分泌抑制剤、及び毛穴目立ち軽減用皮膚外用剤 | |
JP5253821B2 (ja) | インテグリン、ビンキュリン促進剤及びナトリウム依存性ビタミンc輸送体(svct2)の発現促進剤 | |
JP2014125429A (ja) | Dna損傷抑制剤 | |
EP1938827A1 (en) | Novel inhibitor of vascular endothelial growth factor expression | |
JP2011051920A (ja) | 美白剤 | |
JP2007084508A (ja) | 新規血管内皮増殖因子発現阻害剤 | |
KR20180108254A (ko) | 파리신 a를 포함하는 화장료 조성물 | |
JP6823938B2 (ja) | 皮膚外用剤 | |
JP6188881B2 (ja) | ヒアルロン酸合成酵素遺伝子発現促進剤 | |
JP2024055620A (ja) | 美白外用剤、これを含む化粧品、医薬品、及び医薬部外品、並びに皮膚美白方法 | |
JP2019131509A (ja) | Xvii型コラーゲン維持強化剤 | |
KR20170114736A (ko) | 피부 상태 개선용 조성물 | |
KR20170114741A (ko) | 피부 상태 개선용 조성물 | |
KR20110101715A (ko) | 주름 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13841176 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014538657 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157010860 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013841176 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14431837 Country of ref document: US |